NasdaqGM - Nasdaq Real Time Price USD

RAPT Therapeutics, Inc. (RAPT)

Compare

0.7905

-0.0106

(-1.32%)

At close: April 17 at 4:00:01 PM EDT

0.7899

-0.00

(-0.08%)

After hours: April 17 at 5:33:50 PM EDT

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designe

GlobeNewswire 2 days ago

RAPT
-1.32%
RAPT Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2

GlobeNewswire last month

RAPT
-1.32%
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. “Our focus for 2025 will be on advancing development of RPT904, a novel, potentia

GlobeNewswire last month

RAPT
-1.32%
Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer

The company carried out the trial in partnership with MSD and RAPT Therapeutics.

Clinical Trials Arena last month

RAPT
-1.32%
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy

Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

RAPT
-1.32%
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:0

GlobeNewswire 3 months ago

RAPT
-1.32%
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a

GlobeNewswire 3 months ago

RAPT
-1.32%
CTNM
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, announced that they have entered into an exclusive license agreement for JYB1904, or RPT904, a clinical-stage, half-life extended anti-immunoglobulin E monoclonal antibody. Rapt plans to pursue development of RPT904 initially in food allergy, which is a market that represents “a large and lucrative niche,”

TipRanks 3 months ago

RAPT
-1.32%
Progressive, EverQuote upgraded: Wall Street's top analyst calls

Progressive, EverQuote upgraded: Wall Street's top analyst calls

The Fly 3 months ago

EVER

RAPT
-1.32%
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement

Under the licence terms, Jemincare is set to obtain an upfront payment of $35m.

Pharmaceutical Technology 3 months ago

RAPT
-1.32%
Why RAPT Therapeutics Stock Gained Over 100% On Monday?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria

Benzinga 3 months ago

RAPT
-1.32%
RAPT Therapeutics Announces $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $

GlobeNewswire 3 months ago

RAPT
-1.32%
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) --

GlobeNewswire 3 months ago

RAPT
-1.32%
RAPT Therapeutics Reports Third Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2024. Financial Results for the Third Quarter and Nine Months Ended September 30, 20

GlobeNewswire 5 months ago

RAPT
-1.32%
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

The trials were placed on hold earlier this year due to a serious adverse event in a patient.

Clinical Trials Arena 5 months ago

RAPT
-1.32%
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunitiesSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it is terminating its zelnecirnon (

GlobeNewswire 5 months ago

RAPT
-1.32%
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

RAPT
-1.32%
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other Worst 52-Week Low Stocks. The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the […]

Insider Monkey 6 months ago

RAPT
-1.32%
^GSPC
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where RAPT Therapeutics, Inc. (NASDAQ:RAPT) stands against the other worst 52-week low stocks to buy now according to short sellers. The U.S. Federal Reserve conducting a […]

Insider Monkey 6 months ago

RAPT
-1.32%
^GSPC
RAPT Therapeutics Reports Second Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the second quarter and six months ended June 30, 2024. “We continue to analyze the data from our two Phase 2 trials of zelnecirnon (RPT193

GlobeNewswire 8 months ago

RAPT
-1.32%

Performance Overview

Return	RAPT	S&P 500 (^GSPC)
YTD	-49.97%	-10.18%
1-Year	-90.17%	+5.19%
3-Year	-96.20%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RAPT Therapeutics, Inc. (RAPT)

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Progressive, EverQuote upgraded: Wall Street's top analyst calls

RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement

Why RAPT Therapeutics Stock Gained Over 100% On Monday?

RAPT Therapeutics Announces $150 Million Private Placement

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Performance Overview